In United States
Lupin announced the launch of its Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base) having received an approval from the United States Food and Drug Administration earlier. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the organism.Lupin's Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base), is an AT1 rated generic equivalent of Novartis Pharms Corp.'s Vigamox Opthalmic solution.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
